SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-000963
Filing Date
2022-01-06
Accepted
2022-01-06 16:30:26
Documents
14
Period of Report
2022-01-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea153620-8k_allarity.htm   iXBRL 8-K 39121
2 PRESS RELEASE DATED JANUARY 3, 2022 - ALLARITY THERAPEUTICS AND ONCOHEROES BIOSC ea153620ex99-1_allarity.htm EX-99.1 27587
3 GRAPHIC ex99-1_001.jpg GRAPHIC 12839
  Complete submission text file 0001213900-22-000963.txt   270909

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20220102.xsd EX-101.SCH 3025
5 XBRL LABEL FILE allr-20220102_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE allr-20220102_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT ea153620-8k_allarity_htm.xml XML 3713
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 22515149
SIC: 2834 Pharmaceutical Preparations